Inactive Instrument

Oncologix Tech, Inc. Stock Other OTC

Equities

OCLG

US68230M2098

Investment Holding Companies

Financials (USD)

Sales 2013	0.24	Sales 2014	3.68	Capitalization	758K
Net income 2013	-	Net income 2014	-1M	EV / Sales 2013	8,716,069 x
Net Debt 2013	1.33M	Net Debt 2014	1.89M	EV / Sales 2014	721,342 x
P/E ratio 2013	-1.03 x	P/E ratio 2014	-0.47 x	Employees	-
Yield 2013 *	-	Yield 2014	-	Free-Float	99%

More Fundamentals * Assessed data

Chart Oncologix Tech, Inc.

Duration

Period

Style

Dynamic Chart

Latest news about Oncologix Tech, Inc.

DNAGO.Ai entered into a definitive business combination agreement to acquire Oncologix Tech, Inc. in a reverse merger transaction.	22-05-01	CI
Oncologix Tech, Inc. Announces Management Changes	16-12-02	CI
Oncologix Tech, Inc. announced that it expects to receive $10 million in funding from Diversified Innovative Marketing Enterprises Limited	16-08-30	CI
Oncologix Tech, Inc. Announces Board Changes	16-06-24	CI
Oncologix Tech, Inc. Appoints Nikole Jessie as Director of Marketing and Public Relations	15-07-29	CI
Oncologix Tech Inc. Reports Revenue Results Third Quarter and Nine Months Ending May 31, 2015	15-07-21	CI
Oncologix Tech Eyes Acquisitions	15-07-21	CI
Oncologix Tech, Inc. Announces Earnings Results for the Second Quarter and Revenue Results for the Six Months Ended February 28, 2015; Provides Earnings Guidance for the Third Quarter and Full Year of Fiscal 2015	15-04-14	CI
Oncologix Seeks Acquisitions	15-04-14	CI
Oncologix Tech, Inc. Reports Earnings Results for the First Quarter Ending November 30, 2014; Provides Earnings Guidance for Second Quarter of 2015	15-01-16	CI
OCLG Mulls Acquisitions	14-12-30	CI
Oncologix Tech Mulls Acquisitions	14-10-07	CI
Oncologix Tech, Inc. acquired Esteemcare Inc. from Madhu Mathew Mammen and Imad Siddiqui for $0.5 million.	14-10-02	CI
Oncologix Tech, Inc. Announces Revenue Results for the Second Quarter and Half Year Ended February 28, 2014	14-04-21	CI
Oncologix Tech Inc. Closes $4,000,000 Revolving Credit Facility from Senior Lender	14-01-08	CI

More news

Press releases Oncologix Tech, Inc.

DNAGO and Oncologix Tech, Inc. Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Providing clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at affordable price	22-05-02	GL
DNAGO and Oncologix Tech, Inc. Announce Agreement for Business Combination to Create Publicly Listed Company Focused on Providing clinical genetic testing on all 20,000+ genes encompassing 7,000+ rare genetic diseases at affordable price	22-05-02	AQ

More press releases

Managers and Directors - Oncologix Tech, Inc.

Managers	Title	Age	Since
Frank Igwealor CEO	Chief Executive Officer	53	21-06-24
Nikole Jessie IRO	Public Communications Contact	-	15-05-31

Members of the board	Title	Age	Since
Frank Igwealor CEO	Chief Executive Officer	53	21-06-24

More insiders

Company Profile

Oncologix Tech, Inc. is a shell company. The Company is a non-operating holding Company. The Company has no operations. The Company seeks to acquire an operating company via reverse merger.

Sector

Investment Holding Companies

More about the company

Sector Shell Companies

	1st Jan change	Capi.
SCREAMING EAGLE ACQUISITION CORP.	+1.60%	1.01B
CHURCHILL CAPITAL CORP VII	+2.00%	981M
ILEARNINGENGINES, INC.	-35.43%	924M
APPLE ISPORTS GROUP, INC.	+41.91%	872M
PERELLA WEINBERG PARTNERS	+30.17%	851M
ARES ACQUISITION CORPORATION II	+1.63%	663M
E7 GROUP	+0.54%	610M
DA ZHONG TRADING GROUP HOLDING COMPANY	-.--%	600M
ALTC ACQUISITION CORP.	+19.13%	542M

Shell Companies